WuXi Biologics (Cayman) Inc. (HKG: 2269)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 63.05B |
| Revenue (ttm) | 18.39B |
| Net Income (ttm) | 2.83B |
| Shares Out | 4.10B |
| EPS (ttm) | 0.64 |
| PE Ratio | 23.83 |
| Forward PE | 14.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,529,435 |
| Open | 15.06 |
| Previous Close | 14.86 |
| Day's Range | 14.94 - 15.42 |
| 52-Week Range | 10.14 - 49.70 |
| Beta | 0.63 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 21, 2024 |
About WuXi Biologics
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufact... [Read more]
Financial Performance
In 2023, WuXi Biologics's revenue was 17.03 billion, an increase of 11.56% compared to the previous year's 15.27 billion. Earnings were 3.40 billion, a decrease of -23.09%.
Financial numbers in CNY Financial StatementsNews
WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line
LEVERKUSEN, Germany , Nov. 13, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it wi...
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
SHANGHAI , Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of W...
WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year
HONG KONG , Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has rec...
Chinese biotechs gain as drugmakers targeted in new security bill said to mull divestments
China-based drugmakers WuXi AppTec (WUXIF) and WuXi Biologics (WXIBF) are considering selling assets amid a U.S. national security bill. Read more here.
WuXi considering selling its Dundalk plant: report
WuXi Biologics, which has a major manufacturing facility outside Dundalk, is considering selling some of its European production facilities, according to a report in the Financial Times.
WuXi AppTec, WuXi Biologics surge in Hong Kong as biotech firms put some operations for sale
The gains were made on the back of a report that said the two firms plan to sell certain overseas operations amid heightened US scrutiny.
Bullish Chinese investors charge into Hong Kong stocks in stimulus-ignited buying frenzy
Alibaba, HKEX and Wuxi Biologics lead the way as net inflows blow past last year’s total in a buying rush ahead of the ‘golden week’ holiday.
WuXi Biologics: Consider Proposed Legislation And Financial Prospects
WuXi Biologics is expected to report a more modest pace of top-line expansion and lower profit margins in fiscal 2024. See why WXIBF stock is a Hold.
WuXi Biologics Included in Hang Seng ESG 50 Index
HONG KONG , Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has be...
Alibaba, WuXi Biologics lead Hong Kong stock rebound on fund inflows, Fed rate focus
Mainland investors were net buyers of HK$11.6 billion worth of Alibaba shares since it became an eligible component in the Stock Connect scheme this week.
Wuxi AppTec and Wuxi Biologics drop on passage of US bill targeting China biotech firms
Shares of Wuxi AppTec and Wuxi Biologics fell after the US House passed a bill that would restrict business with Chinese biotech companies.
US Set To Approve Multiple Bills Targeting Chinese Biotech, EV Companies And More
The U.S. House of Representatives is set to vote on a series of bills aimed at China, including one that would prevent federal contractors from working with Chinese biotech firms. What Happened : The ...
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing
By leveraging its ultra-intensified fed-batch platform, WuXiUI™, WuXi Biologics has completed its first scale-up to 2,000L drug substance (DS) GMP manufacturing, achieving a 4-fold productivity improv...
WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2024 Earnings Call Transcript
WuXi Biologics (Cayman) Inc. (OTCPK:WXXWY) Q2 2024 Earnings Conference Call August 22, 2024 8:30 AM ETCompany ParticipantsLina Fan - Senior Vice President,...
WuXi Biologics (Cayman) Inc. 2024 Q2 - Results - Earnings Call Presentation
WuXi Biologics Reports Solid 2024 Interim Results
Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7%Added 61 new integrated projects, inclu...
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispeci...
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and WuXi Biologics (stock code: 2269.HK) enter into a three-year, multi-target strategic partnership to design an...
WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics
WUXI and SUZHOU, China , Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced tha...
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI , July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been name...
WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment
The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders. The Company made remarkable progress in tackling ...
WuXi Biologics Reports Solid 2023 Annual Results
HONG KONG, March 26, 2024 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organiz...
WuXi Biologics Named to CDP 'A List' for Water Security
SHANGHAI , March 22, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognize...
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
SHANGHAI , March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized...
Hoping For Better Luck, HK Stocks Enter The Year Of The Dragon
Since its launch in 1969, the Hang Seng has always risen in the dragon years, with gains averaging around 14%. But any rally this time could be hampered by uncertainties over the U.S. presidential ele...